101 related articles for article (PubMed ID: 35982119)
1. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
Svane MS; Johannesen HH; Hansen AE; Martinussen C; Bojsen-Møller KN; Hansen ML; Deacon CF; Keller SH; Klausen TL; Loft A; Kjaer A; Löfgren J; Madsbad S; Holst JJ; Wewer Albrechtsen NJ
Int J Obes (Lond); 2022 Nov; 46(11):2058-2062. PubMed ID: 35982119
[TBL] [Abstract][Full Text] [Related]
2. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
[TBL] [Abstract][Full Text] [Related]
3. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
4. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
Kim SH; Abbasi F; Nachmanoff C; Stefanakis K; Kumar A; Kalra B; Savjani G; Mantzoros CS
Diabetes Obes Metab; 2021 Feb; 23(2):489-498. PubMed ID: 33140542
[TBL] [Abstract][Full Text] [Related]
5. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
6. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.
de Luis DA; Diaz Soto G; Izaola O; Romero E
J Diabetes Complications; 2015; 29(4):595-8. PubMed ID: 25825013
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
Stefanakis K; Kokkinos A; Argyrakopoulou G; Konstantinidou SK; Simati S; Kouvari M; Kumar A; Kalra B; Kumar M; Bontozoglou N; Kyriakopoulou K; Mantzoros CS
Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
[TBL] [Abstract][Full Text] [Related]
9. No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes.
Svane MS; Johannesen HH; Martinussen C; Bojsen-Møller KN; Hansen ML; Hansen AE; Deacon CF; Hartmann B; Keller SH; Klausen TL; Loft A; Kjaer A; Madsbad S; Löfgren J; Holst JJ; Wewer Albrechtsen NJ
Diabetes Obes Metab; 2020 Oct; 22(10):1837-1846. PubMed ID: 32495988
[TBL] [Abstract][Full Text] [Related]
10. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
12. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
Feng P; Yu DM; Chen LM; Chang BC; Ji QD; Li SY; Zhu M; Ding SH; Zhang BZ; Wang SL; Li HT; Lin JN; Wang MJ; Guo JC; Liu J; Liu ZD; Wu ST; Yang JH
Acta Pharmacol Sin; 2015 Feb; 36(2):200-8. PubMed ID: 25619391
[TBL] [Abstract][Full Text] [Related]
14. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J; Jeon M; Brooks A
Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
Manigault KR; Thurston MM
Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
[TBL] [Abstract][Full Text] [Related]
18. Effect of liraglutide on dietary lipid-induced insulin resistance in humans.
Koska J; Lopez L; D'Souza K; Osredkar T; Deer J; Kurtz J; Salbe AD; Harman SM; Reaven PD
Diabetes Obes Metab; 2018 Jan; 20(1):69-76. PubMed ID: 28605158
[TBL] [Abstract][Full Text] [Related]
19. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
20. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
Burcelin R; Gourdy P
Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
